Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib

被引:15
作者
Lee, Ji Su [1 ]
Huh, Chang-Hun [2 ]
Kwon, Ohsang [3 ]
Yoon, Hyun-Sun [1 ]
Cho, Soyun [1 ]
Park, Hyun-sun [1 ]
机构
[1] SMG SNU Boramae Med Ctr, Dept Dermatol, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Dermatol, Gyeonggi, South Korea
[3] Seoul Natl Univ Hosp, Dept Dermatol, Seoul, South Korea
关键词
Nail; alopecia areata; tofacitinib; janus kinase inhibitor; onychodystrophy; UNIVERSALIS; TRACHYONYCHIA; IMMUNOTHERAPY; VARIANTS; EFFICACY;
D O I
10.1080/09546634.2018.1466024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: A few anecdotal case reports demonstrated that tofacitinib improved nail changes associated with AA. Objective: To investigate nail changes in patients with AA treated with tofacitinib and evaluate the relationship between nail and hair responses to tofacitinib. Methods: This is a retrospective study of 33 adult patients with moderate-to-severe AA treated with oral tofacitinib monotherapy for at least 4 months. Results: Fifteen patients had nail involvement and demonstrated more severe hair loss than those without nail involvement (p = .040). However, there was no significant difference in hair regrowth between two groups. Of 15 patients with nail involvement, 11 (73.3%) showed improvement regardless of type of nail change; the first improvement was observed at a median of 5 months (range, 1-11) after administration. Nail improvement was associated with neither initial severity of hair loss nor hair response to tofacitinib. Nail improvement tended to occur later than hair regrowth. Conclusions: Oral tofacitinib monotherapy improves nail involvement associated with AA. Nail involvement is not a poor prognosis factor in hair regrowth with tofacitinib treatment and there is no evident relationship between nail and hair responses.
引用
收藏
页码:819 / 822
页数:4
相关论文
共 23 条
[1]   Alopecia areata update Part I. Clinical picture, histopathology, and pathogenesis [J].
Alkhalifah, Abdullah ;
Alsantali, Adel ;
Wang, Eddy ;
McElwee, Kevin J. ;
Shapiro, Jerry .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (02) :177-188
[2]   Transient Efficacy of Tofacitinib in Alopecia Areata Universalis [J].
Anzengruber, Florian ;
Maul, Julia-Tatjana ;
Kamarachev, Jivko ;
Trueb, Ralph M. ;
French, Lars E. ;
Navarini, Alexander A. .
CASE REPORTS IN DERMATOLOGY, 2016, 8 (01) :102-106
[3]   Tofacitinib for the treatment of alopecia areata and variants in adolescents [J].
Craiglow, Brittany G. ;
Liu, Lucy Y. ;
King, Brett A. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (01) :29-32
[4]   Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata [J].
Crispin, Milene Kennedy ;
Ko, Justin M. ;
Craiglow, Brittany G. ;
Li, Shufeng ;
Shankar, Gautam ;
Urban, Jennifer R. ;
Chen, James C. ;
Cerise, Jane E. ;
Jabbari, Ali ;
Winge, Marten C. G. ;
Marinkovich, M. Peter ;
Christiano, Angela M. ;
Oro, Anthony E. ;
King, Brett A. .
JCI INSIGHT, 2016, 1 (15)
[5]   Tofacitinib Citrate for the Treatment of Nail Dystrophy AssociatedWith Alopecia Universalis [J].
Dhayalan, Arjun ;
King, Brett A. .
JAMA DERMATOLOGY, 2016, 152 (04) :492-493
[6]   Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report [J].
Ferreira, Sineida Berbert ;
Scheinberg, Morton ;
Steiner, Denise ;
Steiner, Tatiana ;
Bedin, Gustavo Longhi ;
Ferreira, Rachel Berbert .
CASE REPORTS IN DERMATOLOGY, 2016, 8 (03) :262-266
[7]  
Gandhi V, 2003, Indian J Dermatol Venereol Leprol, V69, P114
[8]   Trachyonychia: A comprehensive review [J].
Gordon, Katherine ;
Vega, Janelle M. ;
Tosti, Antonella .
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2011, 77 (06) :640-645
[9]   Efficacy of tofacitinib in treatment of alopecia universalis in two patients [J].
Gupta, A. K. ;
Carviel, J. L. ;
Abramovits, W. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (08) :1373-1378
[10]   Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib [J].
Jabbari, Ali ;
Dai, Zhenpeng ;
Xing, Luzhou ;
Cerise, Jane E. ;
Ramot, Yuval ;
Berkun, Yackov ;
Sanchez, Gina A. Montealegre ;
Goldbach-Mansky, Raphaela ;
Christiano, Angela M. ;
Clynes, Raphael ;
Zlotogorski, Abraham .
EBIOMEDICINE, 2015, 2 (04) :351-355